CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-09-21): EU agency backs Bayer's Nexavar for liver cancer

Regulatory

EU agency backs Bayer's Nexavar for liver cancer

Last Updated: 2007-09-21 12:34:49 -0400 (Reuters Health)

LONDON (Reuters) - The European Medicines Agency has recommended approval of Bayer and Onyx Pharmaceuticals' oral medication Nexavar (sorafenib) as a treatment for liver cancer, the agency said on Friday.

The drug is already approved in Europe and the United States for kidney cancer.

It became the first medication to extend the life of patients with advanced liver cancer in a large study -- adding about 3 months to survival compared with a placebo -- according to trial results released in June.

Recommendations for marketing approval by the European agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

Nexavar is also being tested against several other types of cancer, including non-small cell lung cancer and breast cancer.

The drug is being reviewed as a treatment for liver cancer in the United States.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.